Assessment of Antithrombotic Therapy in Patients with Atrial Fibrillation for 2015-2017 According to the Registry of the Clinic of the Scientific Research Institute of Medical Problems of the North of Krasnoyarsk City

Abstract

Aim. To evaluate the volume of antithrombotic therapy (ATT) at the prehospital stage in connection with the risk of thromboembolic complications, and also to study the dynamics of the frequency of administration of oral anticoagulants (ОAC) in patients with atrial fibrillation (AF) in 2015-2017.Material and methods. The registry included 562 patients with AF at the age of 18 years and older, hospitalized in the cardiology department during 2015-2017. The registry did not include patients with AF and mechanical heart valves, mitral stenosis. The diagnosis of AF was established in accordance with the current recommendations. All patients had an assessment of the risk of thromboembolic complications on the CHA2DS2-VASc scale, the risk of bleeding on the HAS-BLED scale. The incidence of ATT at the prehospital stage was assessed depending on the risk of thromboembolic complications based on patient questioning and analysis of medical records. In addition, an assessment of the dynamics of the frequency of the OAC prescription during 2015-2017 was conducted.Results. The overwhelming majority of patients with AF (96.1%) belonged to the group of high-risk of cardioembolic strokes according to the CHA2DS2-VASc scale and had indications for OAC therapy. The frequency of OAC prescription in patients with AF who were admitted to the cardiology department was 32% at the prehospital stage, of which 19.8% of patients took warfarin and 12.2% – direct OAC. The target level of the international normalized ratio (from 2.0 to 3.0) at the time of hospitalization was observed only in 33.6% of patients taking warfarin. Over the observation period, there was a tendency to increase the frequency of OAC prescription from 30% in 2015 to 38.4% in 2017.Conclusion. Only 32% of patients with AF and high risk of thromboembolic complications received adequate antithrombotic therapy at the prehospital stage. According to the registry the frequency of OAC prescription in patients with AF during 2015-2017 increased by 8.4%. At the same time, there was a significant increase in the frequency of direct OAC prescription.

Changes in Prescribing Antithrombotic Therapy in Patients with Atrial Fibrillation in the Multidisciplinary Hospital in Volgograd from 2012 to 2020

“…Несмотря на возможные ошибки и допущения в отношении профилактики ТЭО у пациентов с ФП со стороны врачей, качество фармакотерапии неуклонно улучшается, что подтверждается результатами данного исследования и других подобных работ -снижается частота назначения антиагрегантов, увеличивается назначение антикоагулянтов [14,17,18]. Подобная тенденция может быть связана, с одной стороны, с активным внедрением клинических рекомендаций в практическую деятельность врачей, а с другой -с появлением нового класса препаратов, обладающих более благоприятным профилем безопасности и удобством применения.…”

Dynamics of Kidney Function in Patients with Chronic Kidney Disease and Atrial Fibrillation Who Receive Dabigatran

“…Фибрилляция предсердий (ФП) -наиболее распространенная разновидность наджелудочковых нарушений ритма сердца -1-2% в общей популяции [1,2]. По данным отечественных регистров частота ФП составляет 2,3% наблюдений при анализе данных региональной поликлиники [2], 4,2% от всех случаев госпитализации за год в многопрофильный стационар [3] и 21-31% от всех госпитализированных за год в кардиологическое отделение [4,7]. ФП является одним из основных патогенетических факторов развития ишемического инсульта, который в настоящее время становится одной из ведущих причин смертности и инвалидизации взрослого населения в развитых странах [1,6].…”